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A B S T R A C T
Background
US Centers for Disease Control guidelines recommend replacement of peripheral intravenous (IV) catheters no more frequently than
every 72 to 96 hours. Routine replacement is thought to reduce the risk of phlebitis and bloodstream infection. Catheter insertion is
an unpleasant experience for patients and replacement may be unnecessary if the catheter remains functional and there are no signs of
inflammation. Costs associated with routine replacement may be considerable. This is an update of a review first published in 2010.
Objectives
To assess the effects of removing peripheral IV catheters when clinically indicated compared with removing and re-siting the catheter
routinely.
Search methods
For this update the Cochrane Vascular Trials Search Co-ordinator searched the Cochrane Vascular Specialised Register (March 2015)
and CENTRAL (2015, Issue 3). We also searched clinical trials registries (April 2015).
Selection criteria
Randomised controlled trials that compared routine removal of peripheral IV catheters with removal only when clinically indicated in
hospitalised or community dwelling patients receiving continuous or intermittent infusions.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data.
Main results
Seven trials with a total of 4895 patients were included in the review. The quality of the evidence was high for most outcomes but was
downgraded to moderate for the outcome catheter-related bloodstream infection (CRBSI). The downgrade was due to wide confidence
intervals, which created a high level of uncertainty around the effect estimate. CRBSI was assessed in five trials (4806 patients). There
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was no significant between group difference in the CRBSI rate (clinically-indicated 1/2365; routine change 2/2441). The risk ratio
(RR) was 0.61 (95% CI 0.08 to 4.68; P = 0.64). No difference in phlebitis rates was found whether catheters were changed according
to clinical indications or routinely (clinically-indicated 186/2365; 3-day change 166/2441; RR 1.14, 95% CI 0.93 to 1.39). This result
was unaffected by whether infusion through the catheter was continuous or intermittent. We also analysed the data by number of
device days and again no differences between groups were observed (RR 1.03, 95% CI 0.84 to 1.27; P = 0.75). One trial assessed all-
cause bloodstream infection. There was no difference in this outcome between the two groups (clinically-indicated 4/1593 (0.02%);
routine change 9/1690 (0.05%); P = 0.21). Cannulation costs were lower by approximately AUD 7.00 in the clinically-indicated group
(mean difference (MD) -6.96, 95% CI -9.05 to -4.86; P ≤ 0.00001).
Authors’ conclusions
The review found no evidence to support changing catheters every 72 to 96 hours. Consequently, healthcare organisations may consider
changing to a policy whereby catheters are changed only if clinically indicated. This would provide significant cost savings and would
spare patients the unnecessary pain of routine re-sites in the absence of clinical indications. To minimise peripheral catheter-related
complications, the insertion site should be inspected at each shift change and the catheter removed if signs of inflammation, infiltration,
or blockage are present.
P L A I N L A N G U A G E S U M M A R Y
Replacing a peripheral venous catheter when clinically indicated versus routine replacement
Background
Most hospital patients receive fluids or medications via an intravenous catheter at some time during their hospital stay. An intravenous
catheter (also called an IV drip or intravenous cannula) is a short, hollow tube placed in the vein to allow administration of medications,
fluids or nutrients directly into the bloodstream. These catheters are often replaced every three to four days to try to prevent irritation
of the vein or infection of the blood. However, the procedure may cause discomfort to patients and is quite costly.
Study characteristics and key results
This review included all of the randomised controlled trials (current up to March 2015), which have compared routine catheter changes
with changing the catheter only if there were signs of inflammation or infection. We measured catheter-related blood stream infection,
phlebitis and other problems associated with peripheral catheters, such as local infection and catheter blockage. There was no difference
between the groups on any of these measures. However, we did find that it costs less, on average, when catheters were replaced when
there was a clinical indication to do so, compared with routine changes.
Quality of the evidence
The overall quality of the evidence was rated as being high for most of the outcomes. There was some uncertainty for the outcome
’catheter related blood stream infection’, so the evidence for that outcome was downgraded to moderate. We found no evidence of
benefit to support current practice of changing catheters routinely every three to four days.
2Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Clinically- indicated versus routine changes for peripheral venous catheter- related complications
Patient or population: pat ients with peripheral venous catheter-related complicat ions
Settings: Hospitals and community sett ings
Intervention: clinically-indicated versus rout ine changes
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Clin-
ically indicated versus
routine changes
Catheter- related
bloodstream infection
Posit ive blood culture
f rom a peripheral vein;
clinical signs of in-
fect ion; no other ap-
parent source for the
bloodstream infect ion
except the intravenous
catheter; and colonised
intravenous catheter t ip
culture with the same
organism as ident if ied
in the blood
Study population RR 0.61
(0.08 to 4.68)
4806
(5 studies)
⊕⊕⊕
moderate1,2,3,4
1 per 1000 1 per 1000
(0 to 5)
Moderate
0 per 1000 0 per 1000
(0 to 0)
Phlebitis
Any def init ion used by
the author
Study population RR 1.14
(0.93 to 1.39)
4806
(5 studies)
⊕⊕⊕⊕
high1,3
68 per 1000 78 per 1000
(63 to 95)
Moderate3
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68 per 1000 78 per 1000
(63 to 95)
All- cause bloodstream
infection
Study population RR 0.47
(0.15 to 1.53)
3283
(1 study)
⊕⊕⊕⊕
high1,3
5 per 1000 3 per 1000
(1 to 8)
Moderate
5 per 1000 2 per 1000
(1 to 8)
Cost
Estmated. Based on
materials and staf f
costs5,6
The mean cost in the in-
tervent ion groups was
AUD $6.96 lower
(9.05 to 4.86 lower)
4244
(3 studies)
⊕⊕⊕⊕
high
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Although pat ients and those recording outcomes were aware of group allocat ion, it seems unlikely that this knowledge would
have af fected results. None of those recording outcomes were invest igators and the diagnosis was based on verif iable
data in pat ients medical records.
2 In three of the f ive trials, no CRBSI occurred in either arm of the study. In the other two trials there was considerable overlap
in the conf idence intervals, consequent ly there was no stat ist ical heterogeneity.
3 Part icipants, intervent ions and outcomes were sim ilar across studies.
4 Conf idence intervals were wide for this outcome, indicat ing a level of uncertainty around the ef fect size.
5 The overall cost for cannula replacement varies by cost of materials, t ime, solut ions, addit ives to the solut ion.
6 Mean cost is reported in Australian dollars.
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B A C K G R O U N D
Among hospitalised patients, vascular access is the most common
invasive procedure with 80% of hospital admissions involving an
average of two vascular access devices per patient (Hadaway 2012).
Peripheral intravenous access is associated with a phlebitis rate
of between 1.5% (Malyon 2014) and 60% (Gupta 2007) and a
peripheral intravenous catheter-related bacteraemia (CRBSI) rate
of approximately 0.1% (Maki 2006). Current guidelines recom-
mend that “there is no need to replace peripheral catheters more
frequently than every 72 to 96 hours to reduce risk of infection and
phlebitis in adults” (O’Grady 2011) but most hospitals interpret
this to mean ’change peripheral catheters every 72-96 hours’. The
2011 recommendation carries a category rating of 1B (strongly
recommended for implementation and supported by some exper-
imental, clinical or epidemiological studies). In support of the
rating, the guideline cites two observational studies (Lai 1998;
Tager 1983) and one RCT. The first observational study followed
3094 patients through their period of IV peripheral catheterisation
and found that the phlebitis rate was 3.2% among those whose
catheters remaining in situ for > seven days, compared with a rate
of 4.1% and 3.9% for those whose dwell times were three and four
days respectively (Tager 1983). The second observational study
compared intravenous catheters left in place for 72 hours or 96
hours and found equivalent phlebitis rates (Lai 1998). The one
RCT that was cited was designed to compare two types of catheter
material, not dwell times (Maki 1991). The guideline also exempts
children or patients with poor veins from the recommendation. In
recent years, there have been improvements in catheter design and
composition and more recent studies, including an earlier version
of this review (Webster 2010), indicate that the recommendation
may need to be revised. On the other hand, based on level 1 evi-
dence, themost recent Infusion Nursing Standards of Practice and
the epic3 National Evidence Based Guidelines recommend that
short peripheral catheters should be replaced when clinically indi-
cated, unless the patient is receiving parenteral nutrition peripher-
ally (Infusion Nurses Society 2011; Loveday 2014). The projected
5-year savings from implementing clinically indicated peripheral
intravenous catheter removal policies is US$300 million and 1
million health-worker hours in the United States alone (Tuffaha
2014; Tuffaha 2014a).
Description of the condition
Peripheral vein infusion thrombophlebitis (PVT) is characterised
by pain, erythema (redness of the skin), swelling, and palpa-
ble thrombosis of the cannulated vein (Monreal 1999). Diagno-
sis remains controversial and a number of grading systems have
beenproposed, althoughwith limited validation testing performed
(Ray-Barruel 2014). These include the Maddox scale (Maddox
1977) and the Baxter scale (Panadero 2002), which rank infusion
thrombophlebitis according to the severity of clinical signs and
symptoms. The scales are limited because not all symptomsmay be
present, or theymay not always be present in the clusters described
in the scales. Consequently, many investigators define PVT based
on two or more of pain, tenderness, warmth, erythema, swelling,
and a palpable cord (Maki 1991; Monreal 1999), even though
it may be difficult to distinguish between pain and tenderness.
More recently, a new definition for phlebitis has been proposed,
one based on a more objective assessment of the insertion site
(Rickard 2012). Although the precise pathogenesis of thrombus
formation remains unclear, it is thought to be related to inflam-
mation of the vein wall. Studies have been unable to demonstrate
a high correlation between phlebitis and catheter infection and
Maki has suggested that phlebitis may primarily be a physical re-
sponse (Maki 1991). This was supported byCatney and colleagues
when investigating the aetiology of phlebitis; they found that drug
irritation, size of catheter, and the person inserting the catheter
were all predictors (Catney 2001). Utrasonographic imaging has
demonstrated thrombus formation in two thirds of catheterised
veins studied and it has been suggested that catheter design may
be implicated (Everitt 1997). Thus, possible causes of phlebitis are
mechanical irritation from the catheter and the properties of the
infusate or intravenously administered medications.
Description of the intervention
The intervention under consideration is replacing an intravenous
peripheral catheter only if there are clinical indications to do so.
Clinical indications include blockage, pain, redness, infiltration,
swelling, leakage, and phlebitis.
How the intervention might work
Each time a catheter is inserted, the patient’s skin integrity is
breached and a potential portal for pathogens is provided. For ex-
ample, Uslusoy found a significant relationship between the num-
ber of times infusions were inserted and phlebitis (Uslusoy 2008).
Consequently, it may be prudent to limit the frequency of periph-
eral catheter changes as long as there is no clinical reason to do so.
There is some support for this approach fromobservational studies
that have compared outcomes between catheters remaining in situ
for varying periods. In an adequately powered observational study,
which included patients from medical wards and intensive care
units, the investigators were unable to demonstrate any increased
risk of phlebitis beyond the second day (Bregenzer 1998). Sim-
ilarly, in a retrospective study of 784 intravenous catheter starts
the rate of phlebitis on days one and two was 11.5%, dropping
to 3.9% by day four (Homer 1998). The authors concluded that
“there appeared to be less risk in continuing therapy beyond the
third day than re-starting the therapy” (pp 304). Catney 2001
also failed to demonstrate any increase in phlebitis rates with the
passage of time, with failure rates being less at 144 hours (1.9%)
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than at 72 hours (2.5%) (Catney 2001). Similarly, in a prospec-
tive investigation of 305 peripheral catheters there were 10 cases
of infusion phlebitis amongst patients who had their catheter in
situ for less than 72 hours whereas none were reported in patients
where the dwell time was longer (White 2001). In the same study,
there were three cases of post-infusion phlebitis; these all occurred
amongst patients whose peripheral vein infusion catheter had been
in place for less than 72 hours. Even among a high risk popula-
tion of oncology and infectious diseases patients, phlebitis rates
were no different when length of cannulation was dichotomised
to three days or less and more than three days (Cornely 2002).
Why it is important to do this review
These observational studies create uncertainty around theUSCen-
ters for Disease Control (CDC) guidelines relating to peripheral
intravenous catheter management. This uncertainty has led some
hospitals to adopt the practice of re-siting only where there is evi-
dence of inflammation or infiltration (personal communication).
Included in the newCDC recommendations is a statement related
to clinically-indicated (Cl I) replacement in adults, advising that
this was an “unresolved issue” and referencing the previous version
of this review (Webster 2010), which showed ’no difference’ be-
tween the two approaches to re-siting. Making the guidelines even
more difficult to rationalise is the recommendation for peripheral
catheter replacement in children, which states “replace peripheral
catheters in children only when clinically indicated” (O’Grady
2011). References supporting the 2011 recommendation were un-
related to dwell times (Band 1980; Maki 1973) and may indicate
a mistake in the CDC’s reference list (p61) (O’Grady 2011). In-
sertion of a peripheral intravenous catheter can be a painful and
traumatic process and, if unnecessary, adds not only to a patient’s
discomfort but also has significant cost implications for the in-
stitution. There is a clear need to provide direction for clinicians
through systematically reviewing existing studies.
O B J E C T I V E S
To assess the effects of removing peripheral intravenous (IV)
catheters when clinically indicated compared with removing and
re-siting the catheters routinely.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) comparing routine re-
moval of peripheral IV catheters with removal only when clinically
indicated were considered. Cross-over trials were not eligible for
inclusion.
Types of participants
Any patient requiring a peripheral IV catheter to be in situ for at
least three days for the administration of intermittent or continu-
ous therapy (thismay include patients in hospitals, nursing homes,
or in community settings). Participants receiving parenteral fluids
were excluded.
Types of interventions
Any duration of time before routine replacement versus clinically-
indicated replacement will be included. Catheters made from any
type of material (for example metal, plastic); non-coated or coated
with any type of product (for example antibiotic, anticoagulant); or
covered by any type of dressing (for example gauze, clear occlusive)
were eligible.
Types of outcome measures
Primary outcomes
• Catheter-related blood stream infection (CRBSI) (defined
as a positive blood culture from a peripheral vein; clinical signs of
infection; no other apparent source for the bloodstream infection
except the intravenous catheter; and colonised intravenous
catheter tip culture with the same organism as identified in the
blood)
• Thrombophlebitis (using any definition identified by the
trial author)
• All-cause bloodstream infection (defined as a any positive
blood culture drawn from a peripheral vein while an intravenous
catheter is in situ or for 48 hours after removal)
• Cost (in terms of materials and labour associated with IV
catheter-related insertion)
Secondary outcomes
• Infiltration (defined as permeation of IV fluid into the
interstitial compartment, causing swelling of the tissue around
the site of the catheter)
• Catheter occlusion or blockage (identified by the inability
to infuse fluids)
• Number of catheter re-sites per patient
• Local infection
• Mortality
• Pain
• Satisfaction
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Search methods for identification of studies
There was no restriction on language. If foreign language studies
had been found, we intended to seek initial translation of abstracts
for the application of the inclusion and exclusion criteria. Where
necessary, themethods, results, and discussion sectionswould have
been translated for inclusion in the review.
Electronic searches
For this update the Cochrane Vascular Trials Search Co-ordinator
(TSC) searched the Cochrane Vascular Specialised Register (last
searchedMarch 2015) and theCochraneRegister of Studies (CRS)
(http://www.metaxis.com/CRSWeb/Index.asp) (2015, Issue 2).
See Appendix 1 for details of the search strategy used to search the
CRS. The Cochrane Vascular Specialised Register is maintained
by the TSC and is constructed from weekly electronic searches
of MEDLINE, EMBASE, CINAHL, AMED, and through hand-
searching relevant journals. The full list of the databases, journals,
and conference proceedings which have been searched, as well as
the search strategies used, are described in the Specialised Register
section of the Cochrane Vascular module in the Cochrane Library
(www.cochranelibrary.com).
Searching other resources
We contacted researchers and manufacturers in order to obtain
any unpublished data. Reference lists of potentially useful articles
were also searched.
We also searched the following clinical trials registries;.
• ClinicalTrials.gov (http://clinicaltrials.gov/) (10 April
2015) using the terms peripheral and catheter and routine
• World Health Organization International Clinical Trials
Registry Platform (ICTRP) (http://apps.who.int/trialsearch/)
(10 April 2015) using the terms peripheral and catheter
Data collection and analysis
Selection of studies
Titles and abstracts identified through the search process were in-
dependently reviewed by JW, SO, and CR. Full reports of all po-
tentially relevant trials were retrieved for further assessment of eli-
gibility based on the inclusion criteria. As the review authors were
also the investigators on some of the included trials, assessment
was allocated to a review author who was not an investigator. Dif-
ferences of opinion were settled by consensus or referral to a third
review author. There was no blinding of authorship.
Data extraction and management
Following Cochrane Vascular recommendations, two review au-
thors independently extracted data to a pre-tested data extraction
form. Disagreements were resolved by discussion and, where nec-
essary, by a third review author.We contacted authors of published
and unpublished trials for additional information.
We extracted the following main sets of data from each included
study:
• lead author, date;
• study participant inclusion criteria;
• country where the research was conducted;
• participants’ gender and age;
• study design, randomisation processes, allocation
concealment;
• intervention descriptions;
• intervention setting (hospital, home, residential aged care
facilities);
• numbers of participants in each trial arm, withdrawals and
dropouts;
• outcome measures, time(s) at which outcomes were
assessed.
The first review author entered the data intoRevMan,with another
review author checking the data entry accuracy.
Assessment of risk of bias in included studies
Two review authors independently assessed the included studies
using the Cochrane Collaboration tool for assessing risk of bias
(Higgins 2011a). This tool addresses six specific domains, namely
sequence generation, allocation concealment, blinding, incom-
plete outcome data, selective outcome reporting, and other issues
(for example extreme baseline imbalance). Disagreements between
review authors were resolved by consensus or referral to a third
review author. We contacted the investigators of included trials to
resolve any ambiguities.
Measures of treatment effect
For individual trials, effect measures for categorical outcomes in-
cluded risk ratio (RR) with its 95% confidence interval (CI). For
statistically significant effects, the number needed to treat (NNT)
or number needed to harm (NNH)was calculated. For continuous
outcomes the effect measure we used was mean difference (MD)
or, if the scale of measurement differed across trials, standardised
mean difference (SMD), each with its 95% CI. For any meta-
analyses (see below), for categorical outcomes the typical estimates
of RR with their 95% CI were calculated; and for continuous
outcomes the mean difference (MD) or a summary estimate for
SMD, each with its 95% CI, were calculated. Data were analysed
using the Cochrane Collaboration’s Review Manager (RevMan) 5
software.
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Summary of findings tables
To assess the overall body of evidence, we developed a ’Summary
of findings’ table for the four primary outcomes (catheter-related
bloodstream infection; phlebitis; all-cause bloodstream infection;
and cost) using GRADEprofiler. The quality of the body of evi-
dence was assessed against five principle domains: 1) limitations in
design and implementation; 2) indirectness of evidence or gener-
alisability of findings; 3) inconsistency of results, for example un-
explained heterogeneity and inconsistent findings; 4) imprecision
of results where confidence intervals were wide; and 5) other po-
tential biases, for example publication bias or high manufacturer
involvement (Sch nemann 2011).
Unit of analysis issues
It is inadequate merely to compare longer and shorter dwell time
intravenous devices (IVDs) on crude incidence of complications;
this does not take into account the cumulative daily risk inherent
with IVD use. There is clearly a ‘per day risk’ that is present,
and grows with each day of IVD treatment, regardless of how
many IVDs are used over the period of therapy. This cannot be
extrapolated to mean that restricting (removing) individual IVDs
will reduce overall risk. That is, an IVD in situ for seven days
has seven days of exposure to risk compared with an IVD in use
for only three days, but if the patient requires therapy for seven
days in total then using multiple catheters over the period may
not reduce risk but merely divide the same risk between multiple
catheters. Appropriate time comparisons need to be made using
statistics such as Kaplan-Meier analysis, logistic regression, or Cox
proportional models. It is vital that the patient is used as the unit
of measurement (denominator for comparison), not the IVD. If a
patient requires therapy for example for five days, the patient may
have one catheter used for the entire time or alternately multiple
IVDs used over the five days. If the multiple catheters are viewed
independently they may appear to have lower risk per catheter but
the total risk for the patient over the five days may be the same.
We dealt with this by only including studies where data were
available per patient rather than per catheter.Where data were not
originally analysed in this format we contacted the investigators
(for example Van Donk 2009) to get these data. For comparison,
we have also included an analysis of phlebitis per catheter days
where this information was available.
Cross-over trials were not eligible. There were no cluster ran-
domised trials.
Dealing with missing data
If any outcome data remained missing despite our attempts to
obtain complete outcome data from authors, we assessed the risk
of bias of the missing data and decided if the missing data were
at ’low’ or ’high’ risk of bias according to our risk of bias criteria
(Higgins 2011a). if data were considered to be missing at random,
we analysed the available information. If standard deviations were
missing, we planned to impute them from other studies or, where
possible, compute them from standard errors using the formula
SD = SE X
√
N where these were available (Higgins 2008).
Assessment of heterogeneity
We explored clinical heterogeneity by examining potentially influ-
ential factors, for example intervention dwell time, care setting, or
patient characteristics. We assessed statistical heterogeneity using
the I2 statistic (Higgins 2008). This examines the percentage of
total variation across studies due to heterogeneity rather than to
chance. Values of I2 between 50% and 90% may represent sub-
stantial heterogeneity and values over 75% indicate a high level
of heterogeneity. We carried out statistical pooling on groups of
studies which were considered to be sufficiently similar. Where
heterogeneity was absent or low (I2 = 0% to 25%) we used a fixed-
effect model; if there was evidence of heterogeneity (I2 > 25%)
we used a random-effects model. If heterogeneity was high (I2 >
65%) we did not pool the data (Higgins 2003).
Assessment of reporting biases
Reporting biaswas assessed using guidelines in theCochraneHand-
book for Systematic Reviews of Interventions (Higgins 2011a).Where
sufficient study data were available for individual outcomes, fun-
nel plots were developed and inspected for evidence of publication
bias.
Data synthesis
Where appropriate, results of comparable trials were pooled using
a fixed-effect model and the pooled estimate together with its 95%
CI were reported. We conducted a narrative review of eligible
studies where statistical synthesis of data frommore than one study
was not possible or considered not appropriate.
Subgroup analysis and investigation of heterogeneity
Weplanned to analyse potential sources of heterogeneity using the
following subgroup analyses.
1. Type of randomisation (truly randomised versus not
reported).
2. Concealment of allocation (adequate versus not reported).
3. Blinding (patients and clinicians blinded versus open-label).
4. Statement of withdrawals and losses to follow up in each
group (stated versus not stated).
5. Intermittent versus continuous infusion.
Sensitivity analysis
We planned to perform sensitivity analyses to explore the effect of
the following criteria.
1. Concealment of allocation.
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2. Size of studies (< 100 patients versus at least 100 patients).
3. Duration of follow up.
4. Unpublished studies.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
9Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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For this update, there were three additional citations which were
considered potentially relevant following screening of the search
results. Two of these were publications related to an already in-
cluded study (Rickard 2012) and have been added as supplemen-
tary papers. The third was not relevant to this review. No addi-
tional trials were found in our search of trials registries.
Included studies
Because three of the authors of this review were also investigators
in trials under consideration, we allocated the assessment of those
trials to review authors who were not investigators for those par-
ticular studies.
SevenRCTs (Barker 2004;Nishanth 2009; Rickard 2010; Rickard
2012; Van Donk 2009; Webster 2007; Webster 2008) met the
inclusion criteria (see table: Characteristics of included studies for
details).
The seven trials involved a total of 4895 participants, with in-
dividual trial sizes ranging between 42 and 3283. One trial was
carried out in England (Barker 2004), one in India (Nishanth
2009), the remaining five trials were Australian (Rickard 2010;
Rickard 2012; Van Donk 2009; Webster 2007; Webster 2008).
Five of the trials were conducted in single-centre, acute inpatient
settings (Barker 2004; Nishanth 2009; Rickard 2010; Webster
2007; Webster 2008), one was a multi-centre trial in three Aus-
tralian hospitals (Rickard 2012), and one was undertaken in a
community setting (Van Donk 2009).
In six trials (Barker 2004; Nishanth 2009; Rickard 2010; Rickard
2012; Webster 2007; Webster 2008) patients were included if
they were receiving either continuous infusions or intermittent
infusions for medication therapy, whereas the catheters in the
Van Donk 2009 trial were used for intermittent medication ther-
apy only. In five trials (Rickard 2010; Rickard 2012; Van Donk
2009; Webster 2007; Webster 2008) the comparison was be-
tween routine care (planned three-day changes) and clinically-in-
dicated changes. Barker 2004 and Nishanth 2009 compared 48-
hour changes with removal for clinical indications such as pain,
catheter dislodgement, or phlebitis.
Five of the trials (Barker 2004; Rickard 2010; Rickard 2012;
Webster 2007; Webster 2008) used a standard definition of two
or more of the following: pain, warmth, erythema, swelling, or
a palpable cord. Barker 2004 and Nishanth 2009 further classi-
fied phlebitis as either mild, moderate, or severe depending on the
area of erythema (Barker 2004) or on the number of symptoms
(Nishanth 2009). Van Donk 2009 included the same symptoms
as other trials but scored them as either one or two depending on
the severity. A score of two or more was classified as phlebitis, con-
sequently a patient may have had only one symptom, for example
pain, to receive a positive diagnosis.
Power calculations were reported by Nishanth 2009; Rickard
2010; Rickard 2012;Webster 2007;Webster 2008; andVanDonk
2009 but not by Barker 2004. All of the studies had institutional
ethical approval.
Excluded studies
The table Characteristics of excluded studies contains the rea-
sons for excluding nine trials. In summary, two were very small
studies involving the administration of peripheral parenteral nu-
trition. Neither trial compared straightforward routine replace-
ment with clinically-indicated removal (Kerin 1991; May 1996).
One trial (Panadero 2002) compared one group that used the
same catheter both intraoperatively and postoperatively with a
group using two catheters, one during surgery and one postoper-
atively. The Haddad 2006 trial compared 72-hour changes with
96-hour changes, and the Cobb 1992; Eyer 1990; Nakae 2010;
and Rijnders 2004 trials involved central venous catheters. The
other excluded study was not an RCT (Arnold 1977).
Risk of bias in included studies
See individual ’Risk of bias’ tables and Figure 2; Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Generation of random allocation sequence
All of the investigators reported that they used a computer-based
sequence generator (Barker 2004; Nishanth 2009; Rickard 2010;
Rickard 2012; Van Donk 2009; Webster 2007; Webster 2008).
Allocation concealment
Sealed envelopes were used for allocation concealment by Barker
2004; Nishanth 2009; and Van Donk 2009; the remaining four
trials used a central telephone or computer-based service (Rickard
2010; Rickard 2012; Webster 2007; Webster 2008).
Blinding
It was not possible to blind either the participants or the healthcare
providers in any of the trials.
Outcome assessment
The chief investigator assessed outcomes in the Barker 2004 and
the Nishanth 2009 trial. In the Van Donk 2009; Webster 2007;
and Webster 2008 trials, assessment was made by nurses caring
for the patient or by a dedicated IV service nurse. None of the
nurses were blinded to the group allocation but nor were any of
them associated with the trial. In the Rickard 2010 and Rickard
2012 trials, outcome assessment was undertaken by a dedicated
research nurse who was also aware of the allocation.
Incomplete outcome data
A flow chart was not provided by Barker 2004, so the numbers
screened and eligiblewere unclear, norwere any dropouts reported.
There was also an imbalance in the number of participants re-
ported by group in this trial, which may indicate either a failure
in the randomisation process in such a small trial or incomplete
reporting. The number of protocol violations by group was not
reported. There was complete reporting in the other six trials, all
of which provided a flow of participants through each stage and
used intention-to-treat analysis (Nishanth 2009; Rickard 2010;
Rickard 2012; Van Donk 2009; Webster 2007; Webster 2008).
In the Webster 2007; Webster 2008; and Van Donk 2009 trials,
approximately one third of the participants had protocol viola-
tions and in the Rickard 2012 trial, protocol violations occurred
in 16% of the participants. Primarily these were in the routine
replacement groups, where catheters were not replaced within the
specified time period, reflecting day to day clinical practice.
Selective reporting
Study protocols were available for five trials (Rickard 2010;
Rickard 2012; Van Donk 2009; Webster 2007; Webster 2008)
and reporting followed pre-planned analyses. Barker 2004 and
Nishanth 2009 reported on the expected primary outcomes.
Other potential sources of bias
In the Barker 2004 trial there were two definitions of phlebitis,
one of which stated that two symptoms were necessary; yet it ap-
pears that erythema alone was diagnosed as phlebitis, with sever-
ity based on the area of inflammation. The extreme results in the
Nishanth 2009 trial, where 100% of participants in the clinically-
indicated group developed phlebitis compared with 9% in the
two-day change group, suggests that chance or other unknown
bias affected results in this small trial.
Effects of interventions
See: Summary of findings for the main comparison Clinically-
indicated versus routine changes for peripheral venous catheter-
related complications
Routine changes versus clinically-indicated changes
Catheter-related bloodstream infection (Analysis 1.1)
Catheter-related bloodstream infection was assessed in five trials
(4806 patients) (Rickard 2010; Rickard 2012; Van Donk 2009;
Webster 2007; Webster 2008). There were no reported CRBSIs
in three of these trials (Rickard 2010; Van Donk 2009; Webster
2007).When results from the remaining two trials were combined
there was a 39% reduction in the CRBSI rate favouring the clini-
cally-indicated group (clinically-indicated 1/2365; routine change
2/2441). The RR was 0.61 but the confidence intervals were wide,
creating uncertainty around the estimate (95% CI 0.08 to 4.68;
P = 0.64) (Figure 4).
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Figure 4. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.1 Catheter-
related bloodstream infection.
Phlebitis (Analysis 1.2 and Analysis 1.3)
All of the included studies reported incidence of phlebitis (4895
patients). When results of all trials were combined, heterogene-
ity was 65%. Consequently, we conducted a sensitivity analy-
sis and removed the two trials with less than 100 participants,
both of which used a two-day replacement schedule (Barker 2004;
Nishanth 2009). Removing the two trials eliminated the hetero-
geneity (I2 = 0). Data from the remaining studies (4806 partici-
pants) were combined (Rickard 2010; Rickard 2012; Van Donk
2009; Webster 2007; Webster 2008). There was no difference in
this outcome whether catheters were changed according to clini-
cal indications or routinely (clinically-indicated 186/2365; 3-day
change 166/2441; RR 1.14, 95% CI 0.93 to 1.39; P = 0.20). This
result was unaffected by whether the infusion was continuous or
intermittent (Figure 5).
Figure 5. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.2 Phlebitis.
We also analysed the data by number of device days and, again,
no differences between groups were observed (RR 1.03, 95% CI
0.84 to 1.27; P = 0.75) (Analysis 1.3; Figure 6). In the two trials
using a two-day replacement schedule compared with clinically-
indicated changes (Barker 2004; Nishanth 2009), heterogeneity
was over 60% so results were not combined. In the first of these
two trials Barker 2004 reported that 11/26 (42.3%) participants
in the clinically-indicated group developed phlebitis compared
with 1/21 (4.8%) in the two-day change group. Nishanth 2009
diagnosed all of the participants in the clinically-indicated group
(21/21; 100.0%) with phlebitis and 2/21 (9.5%) in the two-day
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group.
Figure 6. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.3 Phlebitis per
device days.
All-cause bloodstream infection (Analysis 1.4)
One trial assessed this outcome (Rickard 2012). There was no
difference in the all-cause bloodstream infection rate between the
two groups (clinically-indicated: 4/1593 (0.02%); routine change
9/1690 (0.05%); P = 0.21) (Figure 7).
Figure 7. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.4 All-cause
bloodstream infection.
Cost (Analysis 1.5)
In each of the three trials measuring this outcome (4244 partici-
pants) (Rickard 2012; Webster 2007; Webster 2008) cannulation
costs, measured in Australian dollars (AUD), were lower by ap-
proximately AUD 7.00 in the clinically-indicated group (MD -
6.96, 95% CI -9.05 to -4.86; P ≤ 0.00001) (Figure 8).
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Figure 8. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.5 Cost.
Infiltration (Analysis 1.6)
A total of four trials assessed infiltration in 4606 participants
(Rickard 2010; Rickard 2012; Webster 2007; Webster 2008). In-
filtration of fluid into surrounding tissues was reported less often
in the routine change group (452/2346; 19.3%) compared with
the clinically-indicated group (518/2260; 22.9%). The RR was
1.17 (95% Ci 1.05 to 1.31; P = 0.004) (Figure 9).
Figure 9. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.6 Infiltration.
Catheter occlusion/blockage (Analysis 1.7)
Five of the seven trials, reporting on 4806 participants, were in-
cluded in this analysis (Rickard 2010; Rickard 2012; Van Donk
2009; Webster 2007; Webster 2008). Rates of catheter failure
due to blockage were similar between groups (clinically-indicated
398/2395 (16.6%); routine replacement 377/2441 (15.40%); RR
1.25, 95% CI 0.91 to 1.71; P = 0.16) (Figure 10).
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Figure 10. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.7 Catheter
blockage.
Local infection (Analysis 1.8)
Among the four trials measuring local infection (Rickard 2010;
Rickard 2012; Webster 2007; Webster 2008) no differences were
found between groups (clinically-indicated 2/2260 (0.09%); rou-
tine replacement 0/2346 (0.0%); RR 4.96, 95% CI 0.24 to
102.98; P = 0.30) (Figure 11).
Figure 11. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.8 Local
infection.
Mortality (Analysis 1.9)
Four deaths occurred in each group in the one trial (Rickard 2012)
that assessed this outcome (RR 1.06, 95% CI 0.27 to 4.23; P =
0.93) (Figure 12).
Figure 12. Forest plot of comparison: 1 Clinically-indicated versus routine change, outcome: 1.9 Mortality.
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The pre-planned outcomes ’number of catheter re-sites per pa-
tient’, ’pain’ and ’satisfaction’ were not reported by the studies in-
cluded in the review.
Subgroup and sensitivity analysis
We planned to conduct subgroup analyses on 1) Type of randomi-
sation (truly randomised versus not reported); 2) Concealment
of allocation (adequate versus not reported) and; 3) Statement of
withdrawals and losses to follow up in each group (stated versus
not stated).However, there were too few studies in these subgroups
to make any meaningful comparisons. Similarly, blinding was not
possible in any of the studies. Nor did we conduct any of our pre-
planned sensitivity analysis (except size of studies for the outcome
’phlebitis’) for similar reasons.
D I S C U S S I O N
Summary of main results
This systematic review analysed catheter-related bloodstream in-
fection, phlebitis, other reasons for catheter failure, and cost with
the intention of comparing routine catheter changes (at between
two and four days) with replacing the catheter only if clinical signs
were apparent.
The primary outcomes of this review suggest that patients are not
adversely affected if the catheter is changed based on clinical indi-
cations rather than routinely, as recommended by the US Centers
of Disease Control (O’Grady 2011). The rate of catheter-related
bloodstream infection was similar in both groups, between 0.0%
and 0.3%, and comparable to that previously reported in prospec-
tive studies (Maki 2006). A marginal but non-significant increase
in the phlebitis rate in the clinically-indicated group was apparent
when data were analysed by patient but became less perceptible
when data were analysed per 1000 device days, which is a more
clinically useful measure. In addition, most cases of phlebitis are
mild in nature, requiring no treatment or removal of the catheter.
There was no indication in our review that phlebitis was a precur-
sor to bloodstream infection.
Catheter failure due to blockage was more frequent in the clin-
ically-indicated group. This could be expected; all catheters will
fail eventually and will need to be replaced if treatment is ongoing.
The outcome is not clinically meaningful, it is simply an indi-
cator of the longer dwell times in the clinically-indicated group.
Since the ‘treatment’ for a blocked catheter is replacement of the
catheter, it would not be of any benefit to the patient to replace
the catheter earlier since it would not reduce the need for replace-
ment, and would instead increase the chance of re-cannulation.
Many catheters do not fail over the course of IV treatment, even
with extended dwell times.
Cost was significantly less, around AUD 7, in the clinically-in-
dicated group. This result was based on three studies and results
were consistent and intuitively logical (fewer catheters, less clin-
ician time and equipment). Although, this is a seemingly small
amount, it corresponds to approximately 11% of catheter-related
expenditure, which may represent a considerable saving to organ-
isations with high use (Figure 8).
Overall completeness and applicability of
evidence
Trials included in this systematic review directly addressed the re-
view question and we were able to conduct a number of meta-
analyses. Apart from the Barker 2004 and Nishanth 2009 trials,
results from the other five trials were quite similar. Participants
were representative of those usually managed in health care. They
included patients in both acute and community settings and mea-
sured outcomes important to clinicians and patients, providing
useful external validity. It has been suggested that insertion and
management by an IV team may explain the inefficacy of routine
replacement to prevent complications (Maki 2008), yet we saw
no effect in trials that had significant numbers inserted by an IV
team (Webster 2007; Webster 2008) or trials where insertion was
by the general medical and nursing staff (Rickard 2010; Rickard
2012). In all of the trials except for Barker 2004 and Nishanth
2009 standard guidelines were followed for the control group, that
is catheters were changed at between 72 and 96 hours, reflecting
usual care. In the Barker 2004 and Nishanth 2009 trials, catheters
were changed every 48 hours. None of the trials, except Rickard
2012, were powered to report on phlebitis alone, and some of
the trials were very small. For example, the studies that showed
statistically lower phlebitis rates in the clinically-indicated group
(Barker 2004; Nishanth 2009) involved just 47 and 42 people
respectively and showed differences between the control and in-
tervention groups that were quite dissimilar to all of the other
studies. Consequently, results of these two trials should be inter-
preted with caution, particularly results from the Nishanth 2009
trial where all patients in the clinically-indicated group developed
phlebitis compared with none in the two-day change group. It
seems unlikely that these results would have occurred by chance
but correspondence with trial authors shed no further light on
these extreme results. There are no other published papers show-
ing phlebitis rates of 100%.
Five of the seven included trials were conducted in Australia; this
imbalance is difficult to understand. It would be useful to see
similar studies from other healthcare systems to test the robustness
of results from this review.
Neither pain nor satisfaction weremeasured in any of the reviewed
studies and would be a useful addition to any future trial.
Quality of the evidence
See Summary of findings for the main comparison
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Limitations in study design and implementation
Risk of bias was assessed according to six components: sequence
generation, allocation concealment, blinding, selective outcome
reporting, incomplete follow up, and other potential biases. All
of the studies avoided selection bias and ensured allocation con-
cealment. The methodological quality of most of the RCTs was
high with one exception. It was not possible to blind the primary
outcome in any of the trials. Blinding was not possible because it
was necessary to identify the catheter as either ’routine change’ or
’clinically indicated’, to prevent inadvertent routine replacement
of catheters in the intervention group. It is unclear if this had any
bearing onoutcomes but the review authors argue that it is unlikely
(Figure 2; Figure 3). In the Barker 2004 and Nishanth 2009 trials,
the investigator was directly involved in diagnosing phlebitis; in all
of the other studies either medical staff, ward nurses, IV therapy
staff, or research nurses evaluated the outcomes. As one author
noted, it is routine practice to record reasons for removal of an
intravenous catheter in the medical record, and it is unlikely that
such entries would be falsified based on group allocation (Webster
2008).
Indirectness of evidence
All of the trials compared routine changes with clinically-indicated
changes.However, five trials used a three to four-day change sched-
ule and two trials changed catheters every two days. Consequently,
three to four-day results may provide indirect evidence for two-day
changes, conversely two-day changes provide indirect evidence for
a three to four-day change schedule. Additionally, only one study
(Nishanth 2009) included patients who were from a developing
country and who were “usually asthenic, many underhydrated/
dehydrated on admission” (personal correspondence), so the evi-
dence may be regarded as indirect for these types of patients.
Unexplained heterogeneity or inconsistency of results
When we combined results of studies that investigated the effect
of different catheter replacement schedules on phlebitis, the het-
erogeneity was high. This was probably due to the different sched-
ules for the routine catheter changes or population differences, or
both. Small sample sizes may also have contributed to the extreme
results, which caused the heterogeneity. We tested these assump-
tions by performing a sensitivity analysis, removing two of the
seven studies. Results of the five trials are presented in the review
text and the Summary of findings table (Summary of findings for
the main comparison).
Imprecision of results
Confidence intervals were wide in the pooled outcomes of
catheter-related bloodstream infection, local infection, and mor-
tality (Figure 4; Figure 11; Figure 12) indicating a high level of
uncertainty around the effect size. Further research is therefore
very likely to have an important impact on the confidence in the
estimate of effect for these outcomes.
Publication bias
We feel confident that our comprehensive electronic searches iden-
tified all existing, published, randomised controlled trials address-
ing the review question.
Potential biases in the review process
Although the authors were investigators in one or more of the in-
cluded trials, clearly described procedures were followed to prevent
potential biases in the review process. A careful literature search
was conducted and the methods we used are transparent and re-
producible. None of the authors has any conflict of interests.
Agreements and disagreements with other
studies or reviews
Our results concur with several prospective observational studies,
which found no additional risk in extending IVD dwell times
(Bregenzer 1998; Catney 2001; Homer 1998; White 2001). We
believe the reason for this is the similarity in the mean dwell times
between the intervention and control arms. Each of the included
studies were pragmatic trials and, in real life, many catheters are
not changed within the prescribed time frames. For example, in
three-day protocols the 72-hour periodmay occur in themiddle of
the night; or a decision may be made to leave an existing catheter
in place if the patient is due for discharge the following day or
if they are thought to have poor veins. Conversely, the catheter
may need to be removed early in any clinically-indicated group if
the patient’s catheter becomes blocked or infiltration or phlebitis
occurs, or the patient is discharged within a couple of days of
catheter insertion.
Our results also support the CDC guidelines for peripheral
catheter replacement in children, which state “replace peripheral
catheters in children only when clinically indicated” (O’Grady
2011). Similarly, in a guideline for timing peripheral intravenous
replacement (Ho 2011) findings from the original version of this
review were replicated (Webster 2010).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The review found no difference in catheter-related bloodstream in-
fection or phlebitis rates whether peripheral intravenous catheters
are changed routinely every 72 to 96 hours or when clinically
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indicated. The consistency in these results, which include a very
largemulti-site study, indicate that healthcare organisations should
adopt a clinically-indicated replacement policy. This would pro-
vide significant cost savings and would also be welcomed by pa-
tients, who would be spared the unnecessary pain of routine re-
sites in the absence of clinical indications. Busy clinical staff would
also reduce time spent on this intervention. To minimise periph-
eral catheter-related complications, the insertion site should be in-
spected at each shift change and the catheter removed if signs of
inflammation, infiltration, or blockage are present.
Implications for research
Any future trial should use standard definitions for phlebitis and
be sufficiently large to show true differences. Based on results from
the meta-analysis in this review, at least 2500 participants would
be required in each arm of any future trial to show a lowering of
phlebitis rates from 8% to 6% (α = 0.05 and 80% power). Neither
pain nor satisfaction were measured in any of the reviewed studies
and would be a useful addition to any future trial. Although costs
were estimated in some of the included trials, a careful economic
analysis of routine versus clinically-indicated replacement would
be helpful for healthcare administrators. There was also some ev-
idence from this review that different results may occur when the
population is drawn from a developing country. Consequently,
trials conducted in a wider variety of healthcare systems would
add to the external validity of the review’s results.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barker 2004
Methods Study design: Single-centre RCT.
Method of randomisation: Computer generated.
Concealment of allocation: Sealed envelopes.
Participants Country: England.
Number: 47 patients in general medical or surgical wards. Clinically indicated: 43
catheters were inserted in 26 patients. Routine replacement: 41 catheters were inserted
in 21 patients
Age: Clinically indicated 60.5 yrs (15.5); routine replacement 62.7 yrs (18.2)
Sex (M/F): Clinically indicated 15/11; routine replacement 14/7.
Inclusion criteria: Hospital inpatients receiving crystalloids and drugs.
Exclusion criteria: Not stated.
Interventions Clinically indicated: Catheters were removed if the site became painful, the catheter
dislodged or there were signs of PVT
Routine replacement: Catheters were replaced every 48 hours.
Outcomes Primary: Incidence of PVTdefined as “the development of two or more of the following:
pain, erythema, swelling, excessive warmth or a palpable venous cord”
Notes PVT was defined as “the development of two or more of the following: pain, erythema,
swelling, excessive warmth or a palpable venous cord”. However, in the discussion, the
author stated that “even a small area of erythema was recorded as phlebitis” (i.e., only
one sign)
It is unclear what proportion of patients were on continuous infusion
Catheters were inserted “at the instruction of the principal investigator”
“All patients were reviewed daily by the principal investigator, and examined for signs of
PVT at the current and all previous infusion sites”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer generated (personal
communication with author).
Allocation concealment (selection bias) Low risk Comment: Sealed envelopes (personal
communication with author).
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: Neither study personnel nor
participants were blinded.
24Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Barker 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: In this small sample, there were
five fewer patients in the routine replace-
ment group. No explanation was provided
for the unequal sample size. No dropouts
or loss to follow up were reported
Selective reporting (reporting bias) Low risk Comment: Phlebitis was the only outcome
planned.
Other bias High risk Comment:The chief investigator allocated
patients and was responsible for outcome
evaluation
No sample size calculation.
Nishanth 2009
Methods Study design: Single-centre RCT.
Method of randomisation: Not stated
Concealment of allocation: Sequentially numbered sealed envelopes.
Participants Country: India.
Number: 42 patients in surgical wards. Clinically indicated: 21. Routine replacement:
21
Age: Clinically indicated 40.2 yrs (15.0); routine replacement 42.9 yrs (15.0)
Sex (M/F): Clinically indicated 17/4; routine replacement 16/5.
Inclusion criteria: Hospital inpatients admitted for major abdominal surgery
Exclusion criteria: Receiving total parenteral nutrition, duration of therapy expected to
be < three days, if a cannula was already in situ, terminally ill patients
Interventions Clinically indicated: Catheters were removed if the site became painful, the catheter
dislodged or there were signs of PVT
Routine replacement: Catheters were replaced every 48 hours.
Outcomes Primary: Incidence of PVTdefined as “the development of two or more of the following:
pain, erythema, swelling, excessive warmth or a palpable venous cord”
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
Allocation concealment (selection bias) Low risk Quote “group name was placed (on) an
opaque serially numbered sealed envelope
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Nishanth 2009 (Continued)
(SNOSE).”
Comment: Presumably the authors meant
’in’ an opaque serially numbered sealed en-
velope - based on subsequent information
Blinding (performance bias and detection
bias)
All outcomes
High risk Evidence for participants: Quote “un-
blinded study”.
Evidence for personnel: As above.
Evidence for outcomes: As above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment:Data for all patients were avail-
able.
Selective reporting (reporting bias) Low risk Comment: Stated outcomes were reported
but original protocol not sighted
Other bias Unclear risk Extreme results: In this small trial, 100%
of participants in the clinically indicated
group developed phlebitis compared with
9% in the 2-day change group, which sug-
gests that chance or other unknown bias af-
fected results
Rickard 2010
Methods Study design: Single-centre RCT.
Method of randomisation: Computer generated.
Concealment of allocation: Telephone service.
Participants Country: Australia.
Number: 362 patients requiring IV therapy in general medical or surgical wards. Clin-
ically indicated: 280 catheters were inserted in 185 patients. Routine replacement: 323
catheters were inserted in 177 patients
Age: Clinically indicated 62.7 yrs (15.5); routine replacement 65.1 yrs (17.3)
Sex (M/F): Clinically indicated 82/103; routine replacement 81/91.
Inclusion criteria: Patients in over 18 years, expected to have a peripheral intravenous
device (IVD), requiring IV therapy for at least 4 days
Exclusion criteria: Patients who were immunosuppressed, had an existing bloodstream
infection or those in whom an IVD had been in place for > 48 hours
Interventions Clinically indicated: Catheters were removed if there were signs of phlebitis, local
infection, bacteraemia, infiltration or blockage
Routine replacement: Catheters were replaced every 72 - 96 hours.
Outcomes Primary: Phlebitis per person and per 1000 IVD days (defined as two or more of the
following: pain, erythema, purulence, infiltration, palpable venous cord). IVD-related
bacteraemia
Secondary: Hours of catheterisation; number of IV devices; device-related bloodstream
infection; infiltration; local infection
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Rickard 2010 (Continued)
Notes Approximately 75% of patients were receiving a continuous infusion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: Computer generated.
Allocation concealment (selection bias) Low risk Quote “assignment was concealed until
randomisation by use of a telephone ser-
vice”
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: Neither study personnel nor
participants were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Results from all enrolled pa-
tients were reported.
Selective reporting (reporting bias) Low risk Comment: The protocol was available. All
nominated outcomes were reported
Other bias Unclear risk Comment: Significantly more patients in
the routine change group received IV an-
tibiotics (73.1% versus 62.9%)
Rickard 2012
Methods Study design: Multi-centre RCT.
Method of randomisation: Computer generated, stratified by site.
Concealment of allocation: Allocation concealed until eligibility criteria was entered
into a hand-held computer
Participants Country: Australia.
Number: 3283 patients requiring IV therapy in general medical or surgical wards. Clin-
ically indicated: 1593 patients. Routine replacement: 1690 patients
Age: Clinically indicated 55.1 yrs (18.6); routine replacement 55.0 yrs (18.4)
Sex (M/F): Clinically indicated 1022/571; routine replacement 1034/656
Inclusion criteria: Patients, or their representative able to provide written consent; over
18 years, expected to have a peripheral intravenous device (IVD) in situ, requiring IV
therapy for at least 4 days
Exclusion criteria: Patients who were immunosuppressed, had an existing blood stream
infection or those in whom an IVD had been in place for > 48 hours or it was planned
for the catheter to be removed < 24 hours
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Rickard 2012 (Continued)
Interventions Clinically indicated: Catheters were removed if there were signs of phlebitis, local
infection, bacteraemia, infiltration or blockage
Routine replacement: Catheters were replaced every 72 - 96 hours.
Outcomes Primary: Phlebitis during catheterisation or within 48 hrs of removal (defined as two
or more of the following: pain, erythema, swelling, purulent discharge, palpable venous
cord)
Secondary: Catheter-related bloodstream infection, all-cause bloodstream infection, lo-
cal venous infection, colonisation of the catheter tip, infusion failure, number of catheters
per patient, overall duration of intravenous therapy, cost, mortality
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random allocations were com-
puter-generated”.
Allocation concealment (selection bias) Low risk Quote: “Random allocations were com-
puter-generated on a hand-held device, at
the point of each patient’s entry, and thus
were concealed to patients, clinical staff and
research staff until this time”
Blinding (performance bias and detection
bias)
All outcomes
High risk Evidence for participants: Quote “Pa-
tients and clinical staff could not be
blinded”.
Evidence for personnel: Quote “Research
nurses were similarly not masked”.
Evidence for outcomes: Quote “... lab-
oratory staff were masked for rating
of all microbiological end-points, and a
masked, independent medical rater diag-
nosed catheter-related infections and all
bloodstream infections”
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis reported.
Selective reporting (reporting bias) Low risk The protocol was available and all pre-de-
fined outcomes were reported
Other bias Low risk No other known risks of bias.
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Van Donk 2009
Methods Study design: RCT.
Method of randomisation: Computer generated.
Concealment of allocation: Sealed envelopes.
Participants Country: Australia.
Number: 200. Clinically indicated: 105 patients. Routine replacement: 95 patients
Age: Clinically indicated 62.8 yrs (18.2); routine replacement 54.5 yrs (19.0)
Sex (M/F): Not stated.
Inclusion criteria: Adult patients who could be treated at home for an acute illness and
had a 20, 22, or 24 gauge catheter inserted in an upper extremity
Exclusion criteria: Not stated.
Interventions Clinically indicated: Catheters were removed if there were signs of phlebitis, local
infection, bacteraemia, infiltration or blockage
Routine replacement: Catheters were replaced every 72 - 96 hours.
Outcomes Primary: Phlebitis per patient and per 1000 device days (phlebitis was defined as a total
score of 2 or more points from the following factors: pain (on a 10-point scale, 1 = 1
point, and 2 or more = 2 points; redness (less than 1cm = 1 point, and 1 or more cm =
2 points); swelling (as for redness); and discharge (haemoserous ooze under dressing = 1
point, and haemoserous ooze requiring dressing change or purulence = 2 points)
Also reported on: Suspected IVD-related bacteraemia and occlusion/blockage.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment:Computer generated allocation
(personal communication with author)
Allocation concealment (selection bias) Low risk Quote: “Randomizationwas concealed un-
til treatment via sealed envelopes”
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: Neither study personnel nor
participants were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: Participant flow chart pro-
vided. Results from all enrolled patients
were reported
Selective reporting (reporting bias) Low risk Comment: All planned outcomes were re-
ported.
Other bias Low risk No other known risks of bias.
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Webster 2007
Methods Study design: Single-centre RCT.
Method of randomisation: Computer generated.
Concealment of allocation: Allocation concealed until telephone contact made with
an independent person
Participants Country: Australia.
Number: 206. Clinically indicated: 103 patients. Routine replacement: 103 patients
Age: Clinically indicated 60.2 yrs (16.2); routine replacement 63.1 yrs (17.3)
Sex (M/F): Clinically indicated 53/50; routine replacement 54/49.
Inclusion criteria: At least 18 yrs of age, expected to have a peripheral intravenous device
(IVD) in situ, requiring IV therapy for at least 4 days, catheter inserted by a member of
the IV team
Exclusion criteria: Immunosuppressed patients and those with an existing bloodstream
infection
Interventions Clinically indicated: Catheters removed if there were signs of phlebitis, local infection,
bacteraemia, infiltration or blockage
Routine replacement: Catheters replaced every 3 days.
Outcomes Primary: Composite measure of any reason for an unplanned catheter removal
Secondary: Cost (For intermittent infusion: 20 minutes nursing/medical time, a can-
nula, a 3 way tap, a basic dressing pack, gloves, a syringe, transparent adhesive dressing,
skin disinfection and local anaesthetic per insertion. For patients receiving a continuous
infusion: all the above costs plus the additional cost of replacing all associated lines,
solutions and additives which are discarded when an IV catheter is changed (based on
an intravenous administration set, 1 litre sodium chloride 0.09%)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was by computer
generated randomnumber list, stratified by
oncology status”
Allocation concealment (selection bias) Low risk Quote: “Allocation was made by phoning
a person who was independent of the re-
cruitment process”
Blinding (performance bias and detection
bias)
All outcomes
High risk Evidence for participants: Comment:
Participants could not be blinded.
Evidence for personnel: Quote “clinical
staff were subsequently aware of the treat-
ment group”
Evidence for outcomes: Quote: “research
staff had no involvement in nominating the
reason for catheter removal or in diagnosing
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Webster 2007 (Continued)
phlebitis”
“Staff in the microbiological laboratory
were blind to group assignment of catheters
submitted for testing”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: All recruited patients were ac-
counted for in the results.
Selective reporting (reporting bias) Low risk Comment: Protocol was available. All
planned outcomes were reported.
Other bias Low risk No other known risks of bias.
Webster 2008
Methods Study design: Single-centre RCT.
Method of randomisation: Computer generated.
Concealment of allocation: Telephone randomisation.
Participants Country: Australia.
Number: 755. Clinically indicated: 379 patients. Routine replacement: 376 patients
Age: Clinically indicated 60.1 yrs (17.1); routine replacement 58.8 yrs (18.8)
Sex (M/F): Clinically indicated 248/131; routine replacement 233/143.
Inclusion criteria: At least 18 yrs of age, expected to have a IVD in situ, requiring IV
therapy for at least 4 days
Exclusion criteria: Immunosuppressed patients and those with an existing bloodstream
infection
Interventions Clinically indicated: Catheter removed if there were signs of phlebitis, local infection,
bacteraemia, infiltration or blockage
Routine replacement: Catheter replaced every 3 days.
Outcomes Primary: A composite measure of phlebitis (defined as two or more of the following:
pain, erythema, purulence, infiltration, palpable venous cord) and infiltration
Secondary: Infusion-related costs. Cost (For intermittent infusion: 20-minutes nursing/
medical time, a cannula, a 3-way tap, a basic dressing pack, gloves, a syringe, transparent
adhesive dressing, skin disinfection and local anaesthetic per insertion. For patients
receiving a continuous infusion: all the above costs plus the additional cost of replacing
all associated lines, solutions and additives which are discarded when an IV catheter is
changed (based on an intravenous administration set, 1 litre sodium chloride 0.09%)
Individual reasons for catheter failure (occlusion/blockage, local infection)
Also reported: Bacteraemia rate.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Webster 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Block randomisation was by a
computer generated random number list”
Allocation concealment (selection bias) Low risk Quote: “.... telephoned a contact who was
independent of the recruitment process for
allocation consignment”
Blinding (performance bias and detection
bias)
All outcomes
High risk Neither study personnel nor participants
were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All recruited patients were accounted for in
the results.
Selective reporting (reporting bias) Low risk Protocol was available. All planned out-
comes were reported.
Other bias Low risk No other known risks of bias.
IV: intravenous
IVD: peripheral intravenous device
PVT: peripheral vein infusion thrombophlebitis
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnold 1977 Not a randomised controlled trial
Cobb 1992 Involved central, not peripheral lines
Eyer 1990 Involved pulmonary artery or arterial catheters, not peripheral catheters
Haddad 2006 End point was lymphangitis
Kerin 1991 Patients were receiving parenteral nutrition
May 1996 Patients were receiving parenteral nutrition
Nakae 2010 Involved central, not peripheral lines
Panadero 2002 Compared the use of a single intraoperative and postoperative catheters with two catheters, one used intraoperatively
and a separate catheter for postoperative use
32Clinically-indicated replacement versus routine replacement of peripheral venous catheters (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Rijnders 2004 Involved central, not peripheral lines
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D A T A A N D A N A L Y S E S
Comparison 1. Clinically-indicated versus routine change
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Catheter-related blood stream
infection
5 4806 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.08, 4.68]
2 Phlebitis 5 4806 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.93, 1.39]
2.1 Continuous infusion 4 4606 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.89, 1.39]
2.2 Intermittent infusion 1 200 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.85, 1.96]
3 Phlebitis per device days 5 26191 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.84, 1.27]
4 All-cause blood stream infection 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5 Cost 3 4244 Mean Difference (IV, Fixed, 95% CI) -6.96 [-9.05, -4.86]
6 Infiltration 4 4606 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [1.05, 1.31]
7 Catheter blockage 5 4806 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.91, 1.71]
8 Local infection 4 4606 Risk Ratio (M-H, Fixed, 95% CI) 4.96 [0.24, 102.98]
9 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Clinically-indicated versus routine change, Outcome 1 Catheter-related blood
stream infection.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 1 Catheter-related blood stream infection
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 0/185 0/177 Not estimable
Rickard 2012 0/1593 1/1690 59.2 % 0.35 [ 0.01, 8.67 ]
Van Donk 2009 0/105 0/95 Not estimable
Webster 2007 0/103 0/103 Not estimable
Webster 2008 1/379 1/376 40.8 % 0.99 [ 0.06, 15.80 ]
Total (95% CI) 2365 2441 100.0 % 0.61 [ 0.08, 4.68 ]
Total events: 1 (Clinically indicated), 2 (Routine replacement)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Clinically-indicated versus routine change, Outcome 2 Phlebitis.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 2 Phlebitis
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Continuous infusion
Rickard 2010 18/185 12/177 7.5 % 1.44 [ 0.71, 2.89 ]
Rickard 2012 114/1593 114/1690 67.4 % 1.06 [ 0.83, 1.36 ]
Webster 2007 1/103 2/103 1.2 % 0.50 [ 0.05, 5.43 ]
Webster 2008 16/379 12/376 7.3 % 1.32 [ 0.63, 2.76 ]
Subtotal (95% CI) 2260 2346 83.4 % 1.11 [ 0.89, 1.39 ]
Total events: 149 (Clinically indicated), 140 (Routine replacement)
Heterogeneity: Chi2 = 1.29, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
2 Intermittent infusion
Van Donk 2009 37/105 26/95 16.6 % 1.29 [ 0.85, 1.96 ]
Subtotal (95% CI) 105 95 16.6 % 1.29 [ 0.85, 1.96 ]
Total events: 37 (Clinically indicated), 26 (Routine replacement)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
Total (95% CI) 2365 2441 100.0 % 1.14 [ 0.93, 1.39 ]
Total events: 186 (Clinically indicated), 166 (Routine replacement)
Heterogeneity: Chi2 = 1.67, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 0.38, df = 1 (P = 0.54), I2 =0.0%
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Analysis 1.3. Comparison 1 Clinically-indicated versus routine change, Outcome 3 Phlebitis per device days.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 3 Phlebitis per device days
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 18/1120 12/970 7.5 % 1.30 [ 0.63, 2.68 ]
Rickard 2012 114/8693 114/8719 66.3 % 1.00 [ 0.77, 1.30 ]
Van Donk 2009 37/698 26/508 17.5 % 1.04 [ 0.64, 1.69 ]
Webster 2007 1/522 2/548 1.1 % 0.52 [ 0.05, 5.77 ]
Webster 2008 16/2393 12/2020 7.6 % 1.13 [ 0.53, 2.37 ]
Total (95% CI) 13426 12765 100.0 % 1.03 [ 0.84, 1.27 ]
Total events: 186 (Clinically indicated), 166 (Routine replacement)
Heterogeneity: Chi2 = 0.79, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 1.4. Comparison 1 Clinically-indicated versus routine change, Outcome 4 All-cause blood stream
infection.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 4 All-cause blood stream infection
Study or subgroup Clinically indicated Routine replacement Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2012 4/1593 9/1690 0.47 [ 0.15, 1.53 ]
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Analysis 1.5. Comparison 1 Clinically-indicated versus routine change, Outcome 5 Cost.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 5 Cost
Study or subgroup Clinically indicated Routine replacement
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rickard 2012 1593 61.66 (39.46) 1690 69.24 (43.45) 54.5 % -7.58 [ -10.42, -4.74 ]
Webster 2007 103 29.7 (16.4) 103 37.6 (20.2) 17.4 % -7.90 [ -12.92, -2.88 ]
Webster 2008 379 41.05 (26.6) 376 46.22 (28.7) 28.1 % -5.17 [ -9.12, -1.22 ]
Total (95% CI) 2075 2169 100.0 % -6.96 [ -9.05, -4.86 ]
Heterogeneity: Chi2 = 1.11, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 6.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Clinically-indicated versus routine change, Outcome 6 Infiltration.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 6 Infiltration
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 61/185 53/177 12.1 % 1.10 [ 0.81, 1.49 ]
Rickard 2012 279/1593 235/1690 51.1 % 1.26 [ 1.07, 1.48 ]
Webster 2007 43/103 44/103 9.8 % 0.98 [ 0.71, 1.35 ]
Webster 2008 135/379 120/376 27.0 % 1.12 [ 0.91, 1.36 ]
Total (95% CI) 2260 2346 100.0 % 1.17 [ 1.05, 1.31 ]
Total events: 518 (Clinically indicated), 452 (Routine replacement)
Heterogeneity: Chi2 = 2.43, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.87 (P = 0.0041)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Clinically-indicated versus routine change, Outcome 7 Catheter blockage.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 7 Catheter blockage
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rickard 2010 4/185 5/177 5.3 % 0.77 [ 0.21, 2.80 ]
Rickard 2012 344/1593 344/1690 59.3 % 1.06 [ 0.93, 1.21 ]
Van Donk 2009 13/105 4/95 7.4 % 2.94 [ 0.99, 8.71 ]
Webster 2007 7/103 4/103 6.2 % 1.75 [ 0.53, 5.80 ]
Webster 2008 30/379 20/376 21.8 % 1.49 [ 0.86, 2.57 ]
Total (95% CI) 2365 2441 100.0 % 1.25 [ 0.91, 1.71 ]
Total events: 398 (Clinically indicated), 377 (Routine replacement)
Heterogeneity: Tau2 = 0.04; Chi2 = 5.51, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Clinically-indicated versus routine change, Outcome 8 Local infection.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 8 Local infection
Study or subgroup Clinically indicated Routine replacement Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2010 0/185 0/177 Not estimable
Rickard 2012 0/1593 0/1690 Not estimable
Webster 2007 0/103 0/103 Not estimable
Webster 2008 2/379 0/376 100.0 % 4.96 [ 0.24, 102.98 ]
Total (95% CI) 2260 2346 100.0 % 4.96 [ 0.24, 102.98 ]
Total events: 2 (Clinically indicated), 0 (Routine replacement)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Clinically-indicated versus routine change, Outcome 9 Mortality.
Review: Clinically-indicated replacement versus routine replacement of peripheral venous catheters
Comparison: 1 Clinically-indicated versus routine change
Outcome: 9 Mortality
Study or subgroup Clinically indicated Routine replacement Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rickard 2012 4/1593 4/1690 1.06 [ 0.27, 4.23 ]
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A P P E N D I C E S
Appendix 1. CRS search strategy
#1 MESH DESCRIPTOR Infusions, Intravenous EXPLODE
ALL TREES
8726
#2 MESH DESCRIPTOR Catheters, Indwelling EXPLODE
ALL TREES
814
#3 MESH DESCRIPTOR Catheterization, Peripheral EX-
PLODE ALL TREES
635
#4 catheter*:TI,AB,KY 13341
#5 cannul*:TI,AB,KY 1778
#6 (iv near2 (therapy or treatment or device)):TI,AB,KY 530
#7 (intravenous near2 (therapy or treatment or device)):TI,AB,
KY
2162
#8 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 24589
#9 MESH DESCRIPTOR Device Removal EXPLODE ALL
TREES
236
#10 change:TI,AB,KY 65511
#11 routine:TI,AB,KY 14417
#12 (resit* or re-sit* ):TI,AB,KY 18
#13 replace* :TI,AB,KY 17180
#14 remov*:TI,AB,KY 13278
#15 #9 OR #10 OR #11 OR #12 OR #13 OR #14 104860
#16 #8 AND #15 4605
#17 * NOT SR-PVD:CC AND 12/12/2012 TO 31/03/2015:DL 170935
#18 #16 AND #17 882
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WH A T ’ S N E W
Last assessed as up-to-date: 25 March 2015.
Date Event Description
25 March 2015 New citation required but conclusions have not changed Searches re-run. No additional studies included or ex-
cluded. Minor changes to the text to adhere to current
Cochrane standards
25 March 2015 New search has been performed Searches re-run. No additional studies included or ex-
cluded.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The primary outcome was changed to catheter-related bloodstream infection; all-cause bloodstream infection was added as a separate
primary outcome. This was done to more closely differentiate between the two outcomes.
The methodological quality assessment of the included studies has been updated to the Cochrane Collaboration tool for assessing risk
of bias (Higgins 2011a).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Catheter-Related Infections [∗prevention & control]; Catheterization, Peripheral [adverse effects; economics; ∗instrumentation];
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ogy]; Randomized Controlled Trials as Topic; Time Factors
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Humans
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